SHENZHEN, Mar 21, 2025 – (ACN Newswire) – On March 17, China Medical System Holdings Restricted (“CMS” or the “Firm”) launched its 2024 annual outcomes. The Firm recorded a turnover of RMB7,469 million, representing a year-on-year lower of 6.8%; within the case that every one medicines had been straight offered by the Firm, the turnover can be RMB8,622 million, representing a year-on-year lower of 9.0%. Revenue for the 12 months was RMB1,613 million, and normalized revenue for the 12 months that excluding the provisions of impairment losses on associated property was RMB 1,714 million. The outcomes announcement reveals that in 2024, the efficiency decline of the Firm was primarily influenced by the implementation of the Nationwide Quantity Based mostly Procurement (the “Nationwide VBP”), leading to a year-on-year turnover (within the case that every one medicines had been straight offered by the Firm) lower of 28.8% to RMB2,691 million for 3 authentic medicine that weren’t chosen.
Nevertheless, for the Firm, 2024 was each a “12 months of restructuring” amidst challenges and a “12 months of breakthroughs” with rising potentials. Though the general efficiency is experiencing short-term pains, the event of unique and progressive medicine has many highlights and their potential has begun to emerge. In 2024, within the case that every one medicines had been straight offered by the Firm, the turnover of unique and progressive merchandise was RMB4,551 million, representing a year-on-year improve of 4.1%, accounting for 52.8% of the full turnover. This 12 months, the Firm has cumulatively had 5 progressive medicine enter into commercialization, however they had been all within the early market introduction stage. Sooner or later, because the marketed progressive medicine regularly increase into large-scale medical functions and their gross sales ramp up quickly, and because the high quality progressive pipeline continues to be accepted for advertising and marketing, the Firm will enter a brand new cycle of high quality and sustainable improvement pushed by unique and progressive medicine.
In line with the announcement, in 2024, CMS submitted the NDAs for 2 novel medicine in China, together with the progressive drug for the vitiligo therapy, ruxolitinib cream, established three progressive drug collaborations and three medical aesthetic product collaborations. As of the top of 2024, the Firm has amassed a complete of practically 40 short-term, medium-term, and long-term progressive pipeline merchandise. As well as, the Firm’s Southeast Asia enterprise is poised for takeoff. This 12 months, it has promoted greater than 5 progressive medicine to submit market registration functions. The preparatory work for the Singapore manufacturing unit of the related firm has been mainly accomplished, and it’s about to completely launch pharmaceutical CDMO and gross sales promotion companies, cultivating a second development curve.
Product Competitiveness because the Core to Solidify the Innovation Progress Engine
As a pharmaceutical commercialization chief with over three many years of expertise within the pharmaceutical market and having promoted a number of marketed medicine to attain main market positions, CMS additionally maintains a eager market perception when deploying progressive medicine. It selects world FIC (First-in-Class) and BIC (Finest-in-Class) progressive medicine primarily based on front-line market calls for, adhering to the “three-good-variety” screening criterias: having tutorial differentiated benefits, vital market potential and good aggressive panorama, and excessive complete return on funding.
Wanting on the Firm’s marketed progressive medicine, the 5 merchandise both have clear differentiation benefits in comparison with the present merchandise available in the market or fill market gaps specifically areas. Due to this fact, they’ll present beneficial progressive therapy choices for sufferers. For instance, VELPHORO (Sucroferric Oxyhydroxide Chewable Tablets), used for phosphorus discount in power kidney illness (CKD) sufferers, is the primary iron-based, non-calcium phosphate binder (PB) accepted by China’s NMPA, and stuffed the hole of phosphorus-lowering therapy for Chinese language paediatric sufferers aged 12 to 18 years outdated with CKD phases 4-5 or CKD on dialysis. In line with a number of world medical research and real-world analysis knowledge (as printed in tutorial journals together with Worldwide Urology and Nephrology, and Scientific Nephrology) and the Chinese language instruction of the product that in contrast with different PBs, sufferers maintained on VELPHORO used about 50% fewer PB tablets/day, and a proportion of sufferers attaining goal sP elevated by 95%. ILUMETRI (Tildrakizumab Injection) is an progressive organic agent focusing on to the p19 subunit of IL-23 for the therapy of moderate-to-severe plaque psoriasis. It solely requires dosing as soon as each three months in the course of the upkeep interval. With its wonderful long-term efficacy, handy dosing cycle, and good security profile, the affected person compliance is improved. With the wonderful product power because the core and leveraging the wealthy tutorial sources and promotional expertise amassed through the years, the Firm is anticipated to quickly improve the market penetration and model affect of its marketed merchandise.
The Firm’s two progressive medicine, ruxolitinib cream and Desidustat Tablets, that are, at the moment within the NDA evaluation stage in China and anticipated to be launched in 2025, are each thought-about to have good market potential. In line with the announcement, ruxolitinib cream is the primary and solely topical JAK inhibitor accepted by the U.S. FDA and the European EMA for repigmentation in vitiligo as of now. If efficiently accepted for advertising and marketing, it would carry therapy hopes to greater than ten million vitiligo sufferers in China who’re affected by the shortage of efficient medicine. Desidustat Tablets are used for treating anemia in non-dialysis grownup, CKD sufferers and are administered orally. Its Chinese language Part III medical trial reveals that it performs properly in efficacy, security, and tolerability. Knowledge reveals that there are roughly 132 million CKD sufferers in China, and anemia is likely one of the frequent problems. After accepted for advertising and marketing, the product is anticipated to additional meet the anemia therapy wants of CKD sufferers.
As well as, among the many progressive pipeline merchandise that the Firm has reserved and are anticipated to be accepted for advertising and marketing throughout the subsequent 2 to 4 years, there are additionally a number of merchandise with excessive market consideration and industry-assessed potential to turn out to be FIC and BIC blockbuster medicine, equivalent to Y-3 for stroke therapy, the extremely selective small-molecule oral JAK1 inhibitor povorcitinib (for non-segmental vitiligo and hidradenitis suppurativa), the URAT1 inhibitor ABP-671 (for gout), the anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (for atopic dermatitis), the oral improved new drug ZUNVEYL (for Alzheimer’s illness), and so forth. These merchandise will strongly assist the Firm’s steady development in future efficiency.
Notably, CMS has all the time adhered to an environment friendly innovation technique of “Collaborative R&D and In-house R&D” and hooked up nice significance to maximizing the effectivity of R&D funding. From 2018 to 2024, the Firm recorded cumulatively R&D expenditures of round RMB4,350 million, accounting for 7.6% of the turnover throughout the identical interval within the case that every one medicines had been straight offered by the Firm, of which the R&D bills had been RMB880 million, accounting for 1.5% of the turnover throughout the identical interval within the case that every one medicines had been straight offered by the Firm. By comparatively prudent R&D funding, the Firm has efficiently realized the venture initiation, medical improvement, and advertising and marketing of a number of high quality progressive merchandise, attaining extraordinarily excessive innovation input-output effectivity. As well as, as of the top of 2024, the money and financial institution deposit recorded RMB3,707 million, sufficiently safeguarding the continual innovation and in-depth exploration of cutting-edge fields.
Refining the Commercialization System Centered on Specialty to Empower the Launch of Product Worth
The synergy between sturdy product energy and environment friendly commercialization capabilities is the important thing to take care of the aggressive benefit of the Firm. CMS repeatedly upgrades its specialty-focused commercialization system, and types an in-depth structure specializing in core specialties of cardio-cerebrovascular/gastroenterology, dermatology/medical aesthetics, and ophthalmology. Leveraging its amassed intensive skilled promotion networks and tutorial platforms, CMS will safeguard the profitable commercialization of progressive merchandise.
Since its unbiased operation in 2021, “CMS Skinhealth”, is growing right into a “main, innovation-driven pharmaceutical firm in China, specializing in pores and skin well being”. CMS Skinhealth has shaped a complete product portfolio centered on dermatology pharmaceuticals and prolonged to dermatology-grade skincare merchandise and light-weight medical aesthetic merchandise. As of the top of 2024, the dermatology prescription portfolio of CMS Skinhealth has comprehensively coated dermatology ailments, equivalent to vitiligo, psoriasis, atopic dermatitis, phlebitis, varicose veins, and hidradenitis suppurativa. As for dermatology-grade skincare merchandise, the “Heling Soothing Product Sequence”, that are devoted to delicate skincare, have been additional perfected. The Hirudoid® Azelaic Acid Skincare Sequence has been newly launched to supply a complete acne-care resolution. Within the area of sunshine medical aesthetic, the registration software of Poly-L-lactic Acid Microparticle Filler Injection in China has been accepted. Moreover, the Firm has launched three regenerative merchandise, Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant, that are at the moment below the registrational medical trial phases in China, additional enhancing the sunshine medical aesthetic product portfolio. CMS Skinhealth presents a various matrix of dermatological well being and aesthetic merchandise, offering complete and built-in options to people with various wants for pores and skin well being and sweetness.
Concurrently, “CMS Imaginative and prescient”, an independently operated ophthalmology enterprise, focuses on the event and commercialization of ophthalmic pharmaceuticals, medical units, and consumables. In China, a lot of sufferers endure from ophthalmic ailments, and the burden of ophthalmic ailments is growing considerably because of the inhabitants development and getting older. Leveraging on skilled ophthalmic product portfolio, intensive community and channel sources, CMS Imaginative and prescient repeatedly strengthens its model power and tutorial place, aspiring to turn out to be a number one ophthalmic pharmaceutical and gadget firm in China.
As of the top of 2024, CMS had roughly 4,700 skilled advertising and marketing and promotion associated staff, with a promotion community protecting over 50,000 hospitals and medical establishments, and roughly 300,000 retail pharmacies in China. Leveraging its environment friendly advertising and marketing and promotion staff together with an in depth promotion community, the Firm focuses on the marketed progressive medicine and core unique merchandise, dynamically optimizes the advertising and marketing technique, initiates real-world research and post-marketing medical trials, repeatedly accumulates tutorial proof, strengthens the merchandise tutorial affect, and accelerates the transformation into market worth. Concurrently, the Firm has strengthened its growth within the breadth and depth of protection within the out-of-hospital market. By built-in on-line and offline methods and multi-channel collaboration, it has achieved a twin enchancment within the out-of-hospital prescription site visitors diversion and affected person advantages.
Beginning with Southeast Asia and Cultivating the Second Progress Curve of Abroad Enterprise
Whereas deeply growing within the Chinese language market, CMS can also be accelerating its tempo of internationalization. Beginning with Southeast Asia and leveraging the favorable alternative of the quickly rising native demand for prime cost-effective pharmaceutical merchandise, the Firm is actively nurturing the expansion engine of its abroad enterprise, injecting new momentum into its long-term and sustainable improvement.
In 2024, the Southeast Asia enterprise, Rxilient Well being, specializing in regional traits and illness spectrum options, executed a exact planning of its product portfolio and business pathways, and achieved notable milestones within the advertising and marketing registration for a number of merchandise, laying the inspiration for future market promotion and the belief of gross sales. Inside this 12 months, Rxilient Well being has obtained the unique licenses in eleven Southeast Asian nations for povorcitinib, a selective small-molecule JAK1 Inhibitor, with the potential to supply a brand new therapy possibility for sufferers with autoimmune and inflammatory pores and skin ailments. In the meantime, Rxilient Well being is actively advancing the registration of a number of progressive merchandise in Southeast Asia, and/or in Hong Kong, Macau, and Taiwan, together with ruxolitinib cream, ILUMETRI, LUMEBLUE, VALTOCO, VELPHORO and so forth. Amongst them, ruxolitinib cream has been accepted for advertising and marketing in Macau and Hong Kong for the therapy of vitiligo, and in addition submitted the registration functions in Singapore and Taiwan. Moreover, intravenous toripalimab (anti-PD-1 monoclonal antibody drug), collaborated by Rxilient Well being and Junshi Biosciences, has submitted registration functions in Malaysia, the Philippines, Indonesia, Thailand, and Vietnam.
Relating to the CDMO enterprise, the affiliate firm PharmaGend’s manufacturing plant in Tuas, Singapore has obtained the U.S. FDA GMP certification and efficiently handed an on-site inspection by the Singapore HSA. It’s going to present CDMO companies to world pharmaceutical firms and play a important function in making certain the security of the Firm’s abroad manufacturing provide chain.
On the outset of a brand new journey, CMS proactively adapts to vary and strides towards innovation, steadfastly executes the technique of “innovation-driven, effectivity -priority, specialty breakthrough, and worldwide growth”. By reshaping the expansion curve and cultivating a extra diversified and resilient enterprise framework, the Firm is advancing into a brand new section of high quality improvement, offering sufferers with extra high quality therapeutic choices whereas producing long-term steady returns for shareholders.
CMS Disclaimer and Ahead-Wanting Statements
This press launch is just not meant to advertise any merchandise to you and isn’t for promoting functions. This press launch doesn’t advocate any medicine, medical units and/or indications. If you wish to know extra concerning the prognosis and therapy of particular ailments, please observe the opinions or steerage of your physician or different medical and well being professionals. Any treatment-related selections made by healthcare professionals needs to be primarily based on the affected person’s particular circumstances and in accordance with the drug package deal insert.
This press launch which has been ready by CMS doesn’t represent any provide or invitation to buy or subscribe for any securities, and shall not kind the idea for or be relied on in reference to any contract or binding dedication in any way. This press launch has been ready by CMS primarily based on data and knowledge which it considers dependable, however CMS makes no illustration or guarantee, categorical or implied, in any way, and no reliance shall be positioned on, the reality, accuracy, completeness, equity and reasonableness of the contents of this press launch. Sure issues mentioned on this press launch might include statements relating to the Group’s market alternative and enterprise prospects which are individually and collectively forward-looking statements. Such forward-looking statements aren’t ensures of future efficiency and are topic to recognized and unknown dangers, uncertainties and assumptions which are troublesome to foretell. Any forward-looking statements and projections made by third events included on this press launch aren’t adopted by the Group and the Firm is just not answerable for such third-party statements and projections.
Media Contact
Model: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Web site: https://internet.cms.web.cn/en/dwelling/
Supply: China Medical System Holdings Ltd.
Subject: Press launch abstract
Supply: China Medical System Holdings Ltd.
Sectors: Healthcare & Pharm, MedTech
http://www.acnnewswire.com
From the Asia Company Information Community
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Company Information Community.